Live feed13:30:00·35dPRReleasevia QuantisnowAlumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque PsoriasisByQuantisnow·Wall Street's wire, on your screen.ALMS· Alumis Inc.Health Care
